

Regioselective alkylation at the N4 position of a 3-oxo-1,4-benzodiazepine on solid support

Fadia E. Ali*, Catherine C.K. Yuan, Stephen T. Ross & Leon B. Hall

Department of Medicinal Chemistry, Research and Development Division, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939, U.S.A.

Received 16 February 2000; Accepted 3 May 2000


Key words: benzodiazepine, combinatorial array, diversity, Heck reaction, regioselective alkylation, Sasrin® resin

Summary

An efficient solid phase regioselective alkylation at the N4 position of a 3-oxo-1,4-benzodiazepine template exemplified by 4-H-2,3,4,5-tetrahydro-7-iodo-3-oxo-1H-1,4-benzodiazepine-2-acetate-polymer ester is described. Further chemical elaboration at position 7, utilizing a modified Heck reaction, allows the incorporation of amides from primary or secondary amines. The two diversity points at positions 4 and 7 were utilized to synthesize a 28-membered, combinatorial array on Sasrin® resin in moderate yields and > 80% purity. Having validated the chemistry on solid support, a combine and split approach to prepare a bead-bound combinatorial library is achievable utilizing similar experimental practices and procedures as in the array synthesis.

Our interest in developing a robust solid phase synthesis for alkylation of the N4 position of the 1,4-benzodiazepine core molecule (**1**) stemmed from an ongoing vitronectin receptor ($\alpha v\beta 3$) antagonist program. We identified several potent and selective vitronectin receptor ($\alpha v\beta 3$) antagonists through modification of the 7-amido R2 group (**2**) and a few modifications of the N4 substituent [1]. Analogs with modified 7-amido R2 groups were prepared, in solution phase, by coupling of the appropriate amine to the methyl-2,3,4,5-tetrahydro-7-carboxyl-4-substituted-3-oxo-1H-1,4-benzodiazepine-2-acetate ester [2].

Variation of the substituent at the N4 position revealed a trend in the structure-activity relationships that warranted further investigation. Since the route for the solution-phase synthesis requires a separate preparation of each N4-substituted-7-carboxyl-1,4-benzodiazepine-2-acetate, we considered immobilizing the core N4-unsubstituted 1,4-benzodiazepine-2-acetic acid template (**1**) on a polymer-supported




- (1) R = I or Br; R1 = H
(2) R = CONHR2; R1 = Me

resin and carrying out the N4 alkylation step, then incorporating the 7-position substituent. As shown in Scheme 1, the core 4-H-2,3,4,5-tetrahydro-7-iodo-3-oxo-1H-1,4-benzodiazepine-2-acetic acid template (**1**), Scheme 2 [3], was immobilized on super-acid sensitive Sasrin® resin [4] using N,N'-dicyclohexylcarbodiimide (DCC) and 4-pyrrolidino-pyridine [5]. We selected the Sasrin® resin for its facile cleavage with low acid concentration, since we found that the 1,4-benzodiazepine nucleus was unstable for prolonged acid exposure.¹ Anion formation was achieved using 2 equiv of n-butyl lithium or lithium hexamethyldisilazane (HMDS) at low temperature (–78 to –45 °C), followed by the addition of ex-


* To whom correspondence should be addressed. E-mail: fadia_e_ali@sbphrd.com

Table 1. 4-Substituted 2,3,4,5-tetrahydro-7-substituted (methylamino) carbonyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid analogs⁴

No	R1	R	R2	No	R1	R	R2
1		H	H	2		CH ₃	H
3		H	H	4		H	2,4,6,(CH ₃) ₃
5		CH ₃	2,4,6,(CH ₃) ₃	6		H	2,4,6,(CH ₃) ₃
7		H	4-CF ₃	8		CH ₃	4-CF ₃
9		H	4-CF ₃	10		H	2-CH ₃
11		CH ₃	2-CH ₃	12		H	2-CH ₃
13		H	4-NO ₂	14		CH ₃	4-NO ₂
15		H	4-NO ₂	16		CH ₃	3-CN
17		CH ₃	4-OCH ₃	18		CH ₃	4-OCF ₃
19		CH ₃	4-t-Bu	20		CH ₃	2,3,4-F
21		cycl.	H	22		CH ₃	H
23		H	H	24		CH ₃	H
25		CH ₃	2-OCH ₃ -4-NO ₂	26		CH ₃	3-CF ₃
27		CH ₃	H	28		H	H



Scheme 1. (a) Sasrin[®] resin, DCC, 4-pyrrolidinopyridine (15 mole %), DMF, RT, 18 h; (b) 2 equiv n-BuLi, anhydrous distilled THF at -78°C , 90 min, 15 equiv BnBr in DMF at -78°C to RT, 18 h; (c) 2-(aminomethyl) benzimidazole, Hunig's base, bis-(triphenylphosphine) palladium II chloride (0.2 equiv), carbon monoxide balloon, NMP at 110°C , 3 h; (d) 2% trifluoroacetic acid in dichloromethane.



Scheme 2. (a) Triflic anhydride (TfO)₂/pyridine CH_2Cl_2 at 0°C (95%); (b) 2-aminobenzonitrile, 2,6-di-tert-butylpyridine in CHCl_3 /Hex mix for 3 days, flash silica (EtOAc/Hex) (62%); (c) H_2 balloon, Ra Ni, Et_3N , MeOH for 2 days, flash silica (74%), chiral HPLC analysis revealed $\sim 30\%$ of the R-enantiomer; (d) iodomonochloride/pyridine complex (from ICl and pyridine in CH_2Cl_2 at 5°C for 20 min) in 1:1 CH_2Cl_2 /MeOH at RT for 40 min (quant.); (e) 1 N NaOH (1.5 equiv) in 1:1 THF/MeOH, then neutralization (75%).

cess electrophile. Most of the electrophiles used were derivatives of benzyl bromide that provide a range of steric, electron-donating and electron-withdrawing properties.² The resin-bound N4-alkylated template was then reacted with a primary or a secondary amine using palladium (0) catalyzed carboamidation under modified Heck reaction conditions [6, 7]. The amines selected were of interest to the ongoing program. The progress of the reactions on solid support was followed by magic angle spinning ¹H NMR (MAS-NMR). Members of the array were cleaved from the resin using a low concentration (1–2%) of trifluoroacetic acid in dichloromethane solution. Upon cleavage from the resin, all members of the array, shown in Table 1, were characterized using ¹H NMR, HPLC and mass spectral analysis. In each case, a single component was obtained in > 80% purity, allowing for biological screening of the crude products without any further purification³.

Intriguingly, the results that were confirmed by NMR indicated that a regioselective alkylation at N4 over N1 took place⁴. The regioselectivity observed can be attributed to the more acidic nature (lower pK_a value) of the N4 proton (amide) relative to the proton at N1 (aniline) [8]. In addition, we observed no reaction between the organolithium reagents and the aromatic halogen to give a halogen/lithium exchange, nor did these reagents react with the ester to prematurely cleave the compound from the resin.

In conclusion, we have developed an efficient solid-phase procedure to regioselectively alkylate at the N4 position of a 1,4-benzodiazepine that was utilized to produce a 28-membered array. The procedure is amenable for production of larger arrays and a bead-bound combinatorial library utilizing similar experimental practices and procedures as described herein.

Acknowledgements

We thank the departments of analytical chemistry and physical and structural chemistry for their supports in solution ¹H NMR, elemental and mass spectral analysis.

Notes

1. We found that prolonged acid exposure of the 1,4-benzodiazepine molecule resulted in diazepine ring

opening and loss of the 2-carboxyl as a result of oxidative decarboxylation side products.

2. Other alkyl halide, such as methyl iodide was used successfully during the development of the procedure.

3. Alkylation of the N4 position gave 60–80% isolated yield based on weight gain of the resin of the N4 alkylated product; the carboamidation step afforded 30–50% yield of isolated product after cleavage and triturating with diethyl ether. All isolated products were characterized using ¹H NMR, HPLC and mass spectral analysis to indicate a single component, each with > 80% purity.

4. The regioselectivity for the N4 benzylation over N1 was confirmed during the development of the procedure by ¹H NMR using proton correlated spectroscopy (COSY) and ¹³C NMR using heteronuclear multiple bond correlation (HMBC) for proton–carbon 2–3 bonds coupling correlation and heteronuclear multiple quantum coherence (HMQC) for direct proton–carbon coupling correlation. ¹H NMR of these compounds typified by entry 2 using a 360 MHz Bruker AMX3 60 spectrometer maintained at 300 K in DMSO-d₆/TFA: δ 7.8 (m, 2H), 7.55 (m, 2H), 7.19 (s, 5H), 7.17 (m, 1H), 7.1 (d, 1H), 6.58 (d, 1H), 5.48 (d, 1H), 5.15 (m, 1H), 5.0 (s, 2H), 4.75 (d, 1H), 4.4 (d, 1H), 3.85 (d, 1H), 3.10 (s, 3H), 2.85 (dd, 1H), 2.6 (dd, 1H). In developing a model reaction, the stoichiometry of the n-BuLi was varied from 1.1 to 6 equiv and only one regioisomer was observed.

References

- (a) Keenan, R.M., Miller, W.H., Kwon, C., Ali, F.E., Callahan, J.F., Calvo, R.R., Hwang, S.M., Kopple, K.D., Pelshoff, C.E., Samanen, J.M., Wong, A.F., Yuan, C. and Huffman, W.F., *Discovery of potent nonpeptide vitronectin receptor (α_vβ₃) antagonists*, *J. Med. Chem.*, 40 (1997) 2289–2291.
 - (b) Keenan, R.M., Miller, W.H., Lago, M.A., Ali, F.E., Bondinell, W.E., Callahan, J.F., Calvo, R.R., Cousins, R.D., Hwang, S.M., Jakas, D.R., Ku, T.W.; Kwon, C., Nguyen, T.T., Reader, V.A., Reiman, D.J., Ross, S.T., Takata, D.T., Uzinskas, I.N., Yuan, C.K. and Smith, B.R., *Benzimidazole derivatives as arginine mimetics in 1,4-benzodiazepine nonpeptide vitronectin receptor (α_vβ₃) antagonists*. *Bioorg. Med. Chem. Lett.*, 8, (1998) 3165–3170.
 - (c) Keenan, R.M., Lago, M.A., Miller, W.H., Ali, F.E., Cousins, R.D., Hall, L.B., Hwang, S.M., Jakas, D.R., Kwon, C., Loudon, C., Nguyen, T.T., Ohlstein, E.H., Reiman, D.J., Ross, S.T., Samanen, J.M., Smith, B.R., Stadel, J., Takata, D.T., Vickery, L., Yuan, C.K. and Yue, T.L., *Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (α_vβ₃) antagonist with efficacy in a restenosis model*, *Bioorg. Med. Chem. Lett.*, 8 (1998) 3171–3176.
- (a) Miller, W.H., Ku, T.W., Ali, F.E., Bondinell, W.E., Calvo, R.R., Davis, L.D., Erhard, K.F., Hall, L.B., Huffman, W.F.,

- Keenan, R.M., Kwon, C., Newlander, K., Ross, E.T., Samanen, J.M., Takata, D.T. and Yuan, C.K., *Enantiospecific synthesis of SB 214857, a potent orally active nonpeptidefibrinogen receptor antagonist*, *Tetrahedron Lett.*, 36 (1995) 9433–9436.
- (b) Ku, T.W., Ali, F.E., Bondinell, W.E., Erhard, K.F., Huffman, W.F., Venslavsky, J.W. and Yuan, C.K., *An alternative enantiospecific synthesis of methyl (S)-7-tert-butoxycarbonyl-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetate*, *Tetrahedron Lett.*, 38 (1997) 3131–3134.
- Bondinell, W.E., Callahan, J.F., Huffman, W.F., Keenan, R.M., Ku, T.W., Newlander, K.A., Samanen, J.M. and Uzinskas, I.N., *Bicyclic fibrinogen antagonists*, (1995) WO 95/18619, 1–71.
 - Mergler, M., Tanner, R., Gosteli, J. and Grogg, P., *Peptide synthesis by a combination of solid-phase and solution methods I: A new very acid-labile anchor group for the solid-phase synthesis of fully protected fragments*, *Tetrahedron Lett.*, 29 (1988) 4005–4008.
 - Waldmann, H. and Kunz, H., *1,3-Dithian-2-ylmethyl esters as two-step carboxy-protecting groups in the synthesis of N-glycopeptides*, *J. Org. Chem.*, 53 (1988) 4172–4175.
 - (a) Schoenberg, A. and Heck, R.F., *Palladium-catalyzed amidation of aryl, heterocyclic, and vinylic halides*, *J. Org. Chem.*, 39 (1974) 3327–3331.
 - (b) Valentine, D., Tilley, J.W. and LeMahieu, R.A., *Practical catalytic synthesis of anthanilic acids*, *J. Org. Chem.*, 46 (1981) 4614–4617.
 - (c) Mori, M., Ishikura, M., Ikeda, T. and Ban, Y., *New synthesis of diazepinone skeleton using palladium catalyzed carbonylation*, *Heterocycles*, 16 (1981) 1491–1494.
 - (d) Perry, R.J., *Making aramids using CO and palladium catalysis*, *Chemtech*, (1994) 18–23.
 - Etridge, S.K., Hayes, J.F., Walsgrove, T.C. and Wells, A.S., *A new convergent synthesis of (2S)-7-(4,4'-bipiperidinylcarbonyl)-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid using a palladium-catalysed aminocarbonylation reaction*, *Org. Process Res. Dev.*, 3 (1999) 60–63.
 - (a) International Union of Pure and Applied Chemistry, *Dissociation Constants of Organic Bases in Aqueous Solution*, Perrin, D.D., London, Butterworths & Co. Publishers, 1965, p. 65.
 - (b) Druet, L.M. and Yates, K., *Mechanistic variation in the reactions of substituted acetamides in aqueous sulfuric acid*, *Can. J. Chem.*, 62 (1984) 2401–2414.